SCHEMBL23218217

SCHEMBL23218217

CCOC(=O)Cc1ccc(F)cc1OCc1c(C(C)(C)C)oc2ccc(Br)cc12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.40
KMT2A Q03164 3/20 0.40
HPGD P15428 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
MEN1 O00255 2/20 0.40
HTT P42858 2/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
GPR55 Q9Y2T6 1/20 0.40
ALOX5 P09917 3/20 0.38
TSHR P16473 3/20 0.36
MAPT P10636 3/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
CA12 O43570 1/20 0.36
CA9 Q16790 1/20 0.36
LMNA P02545 2/20 0.35
KDM4E B2RXH2 1/20 0.35
MAPK1 P28482 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29853053 1.00 ALDH1A1 (0.40) ALDH1A1KMT2AHPGDSMN1; SMN2MEN1
SCHEMBL23218361 0.91 KMT2A (0.41) ALDH1A1KMT2AHPGDSMN1; SMN2MEN1
SCHEMBL29853241 0.91 KMT2A (0.41) ALDH1A1KMT2AHPGDSMN1; SMN2MEN1
SCHEMBL29853014 0.90 KMT2A (0.42) ALDH1A1KMT2AHPGDSMN1; SMN2MEN1
SCHEMBL23218175 0.90 KMT2A (0.42) ALDH1A1KMT2AHPGDSMN1; SMN2MEN1
SCHEMBL23218983 0.89 ALOX5 (0.40) ALDH1A1KMT2AHPGDSMN1; SMN2MEN1
SCHEMBL29853064 0.89 ALOX5 (0.40) ALDH1A1KMT2AHPGDSMN1; SMN2MEN1
SCHEMBL23218789 0.89 TSHR (0.40) ALDH1A1KMT2AHPGDSMN1; SMN2MEN1
SCHEMBL29852506 0.89 TSHR (0.40) ALDH1A1KMT2AHPGDSMN1; SMN2MEN1
SCHEMBL23218514 0.83 CFD (0.45) ALDH1A1KMT2AHPGDSMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 US disclosed
EP-4041238-A1 ORAL COMPLEMENT FACTOR D INHIBITORS Biocryst Pharmaceuticals, Inc. (US) 2022-08-17 EP disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed
US-20160361275-A1 SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY ACADIA PHARMACEUTICALS INC. 2016-12-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160361275-A1 SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY SLC6A4, HTR4, GPR34 ALDH1A1 3075/4885KMT2A 4413/4885HPGD 3082/4885
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB ALDH1A1 2667/4885KMT2A 4445/4885HPGD 695/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB ALDH1A1 3142/4885KMT2A 4835/4885HPGD 323/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.